CNBCLean R·
We're increasing our Eli Lilly price target after another beat-and-raise quarter
The strength of its GLP-1 business suggests the stock still has more room to run.
Read at CNBC →
Business · 1 sources covering this
We're increasing our Eli Lilly price target after another beat-and-raise quarter
The strength of its GLP-1 business suggests the stock still has more room to run.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/f456650e2c1e786cdc49188f72b2bae5e34e94cb" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="We're increasing our Eli Lilly price target after another beat-and-raise quarter"></iframe>
